進行肝細胞癌治療における Sorafenib の有害事象 : 減量開始例と推奨用量開始例の比較

概要

論文の詳細を見る
We compared with the adverse events of half-dose (400 mg per day, n=13) administration and standard-dose (800 mg per day, n=12) administration of sorafenib as initial-dose treatment for advanced hepatocellular carcinoma. Baseline characteristics such as sex, age, Child Pughs classification, and presence or absence of portal vein thrombosis and extrahepatic metastasis did not differ significantly between the two initial-dose groups. The dose of sorafenib was reduced because of adverse events in 75% of the standard-dose cases and in 38% the half-dose cases. The difference between the two groups in time to radiographic progression was not significant. A randomized, double-blind, study may be necessary to find the optimal dose of sorafenib for treatment of Japanese patients with advanced hepatocellular carcinoma lesions.
2010-07-25